New drug combo aims to shrink aggressive breast tumors before surgery
NCT ID NCT07178171
First seen Sep 30, 2025 · Last updated May 16, 2026 · Updated 33 times
Summary
This early-phase study tests a new immunotherapy drug (QL1706) combined with short cycles of chemotherapy for people with early-stage triple-negative breast cancer (TNBC). TNBC is an aggressive cancer that lacks common targets, making it harder to treat. The trial will enroll 30 participants to see if this combination can eliminate the tumor before surgery, potentially reducing the need for more chemotherapy afterward.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for TNBC, TRIPLE NEGATIVE BREAST CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Xijing hospital
RECRUITINGXi'an, Shaanxi, 710032, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.